Literature DB >> 6415166

The release of platelet-activating factor from human endothelial cells in culture.

G Camussi, M Aglietta, F Malavasi, C Tetta, W Piacibello, F Sanavio, F Bussolino.   

Abstract

The release of platelet-activating factor (PAF) from stimulated human endothelial cells (HEC) cultured from normal term, umbilical cord veins is described. HEC in primary cultures released PAF after challenge with A23187, rabbit anti-human factor VIII (RaHu/FVIII), angiotensin II, and vasopressin. HEC subcultures maintained the ability to release PAF in the presence of A23187 and RaHu/FVIII, whereas the release of PAF in response to angiotensin II and vasopressin was not constant and was reduced. Control cultured, smooth muscle cells derived from umbilical cord veins, previously depleted of endothelial cells, did not release PAF under the above-mentioned stimulation. Plastic-adherent or cultured monocytes released PAF with A23187, but not with RaHu/FVIII, angiotensin II, and vasopressin. The release of PAF from HEC in primary cultures required the presence of extracellular cations and the activation of membrane phospholipase A2. PAF release induced by A23187, RaHu/FVIII, angiotensin II, and vasopressin was unaffected by indomethacin, an inhibitor of cyclooxygenase, which, however, favored the release of PAF from HEC stimulated with thrombin, a stimulus that did not affect HEC in the absence of indomethacin. PGI2 inhibited PAF release from stimulated HEC. The relevance of an acetylation process in the biosynthesis of PAF and HEC was supported by the following evidence: 1) the increase in PAF yield in the presence of sodium acetate and, particularly, of acetyl-CoA; 2) the incorporation of [14C]acetate into PAF molecules; 3) the loss of radioactivity and of biologic activity after treatment with phospholipase A2. These results indicate that HEC in culture are able to release PAF and that metabolic pathways similar to those described for leukocytes are involved.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415166

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  92 in total

1.  Effects of PAF and PAF antagonists on the shape of venous endothelial cells in vitro.

Authors:  A M Northover
Journal:  Agents Actions       Date:  1989-08

2.  Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha.

Authors:  G Montrucchio; E Lupia; A de Martino; E Battaglia; M Arese; A Tizzani; F Bussolino; G Camussi
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

Review 3.  Lung inflammation, its significance for asthma therapy.

Authors:  J Morley; D Smith
Journal:  Agents Actions       Date:  1989-01

Review 4.  Hypoxia and inflammatory synovitis: observations and speculation.

Authors:  C R Stevens; R B Williams; A J Farrell; D R Blake
Journal:  Ann Rheum Dis       Date:  1991-02       Impact factor: 19.103

5.  Calcium-dependent biosynthesis of platelet-activating factor by submandibular gland cells.

Authors:  T Dohi; K Morita; S Kitayama; A Tsujimoto
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

6.  Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate.

Authors:  T M McIntyre; G A Zimmerman; K Satoh; S M Prescott
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

7.  1-O-alkyl-2-acetyl-sn-glycerol: a platelet-activating factor metabolite with biological activity in vascular smooth muscle cells.

Authors:  L L Stoll; P H Figard; N R Yerram; M A Yorek; A A Spector
Journal:  Cell Regul       Date:  1989-11

8.  Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505.

Authors:  F Pons; A G Rossi; K E Norman; T J Williams; S Nourshargh
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  Intravascular release of a platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking.

Authors:  T Imaizumi
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

10.  Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages.

Authors:  M Watanabe; M Yamada; S Mue; K Ohuchi
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.